Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

95.18EUR
11:35am EDT
Change (% chg)

€-3.30 (-3.35%)
Prev Close
€98.48
Open
€96.90
Day's High
€96.90
Day's Low
€94.88
Volume
1,404,648
Avg. Vol
396,973
52-wk High
€115.20
52-wk Low
€90.00

Select another date:

Fri, Jul 21 2017

BRIEF-Merck KGaA and Pfizer: CHMP recommends approval of avelumab

* EMA’S CHMP ISSUES POSITIVE OPINION FOR AVELUMAB FOR THE TREATMENT OF METASTATIC MERKEL CELL CARCINOMA

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma.

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

July 21 European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma.

BRIEF-Merck KGaA refines Western European Life Science Production site network

* REFINES WESTERN EUROPEAN LIFE SCIENCE PRODUCTION SITE NETWORK

EU charges Merck KGaA, GE, Canon of misleading merger info

BRUSSELS, July 6 EU antitrust regulators accused German drugmaker Merck KGaA, General Electric and Japan's Canon of providing misleading information during their merger deals, as regulators stepped up their crackdown on such practices.

Germany's Merck gets EU backing for oral MS drug

(This June 23 story corrects second paragraph to show that the recommendation is to approve the relapsing forms, not the relapsing-remitting form of MS.)

CORRECTED-Germany's Merck gets EU backing for oral MS drug

FRANKFURT, June 23 Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed.

BRIEF-EMA recommends approval of Merck's multiple sclerosis drug

* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug

BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer

* Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer

BRIEF-Merck awarded first CRISPR patent by Australian patent office

* Awarded first CRISPR patent by Australian patent office Further company coverage:

Select another date: